清脑醒神汤联合倍他司汀治疗周围性眩晕的临床疗效及其安全性  

Clinical efficacy and safety of Qingnaoxingshen decoction combined with betahistine for peripheral vertigo

作　　者：易永杜 YI Yongdu(Department of Encephalopathy,Maoming Hospital of Traditional Chinese Medicine,Maoming 525000,China)

机构地区：[1]广东省茂名市中医院脑病科,525000

出　　处：《临床合理用药杂志》2020年第12期21-22,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的探讨清脑醒神汤联合倍他司汀治疗周围性眩晕的临床疗效及其安全性。方法选取茂名市中医院2018年收治的周围性眩晕患者80例,根据随机数字表法分为对照组和观察组,各40例。对照组给予倍他司汀治疗,观察组在对照组基础上给予清脑醒神汤治疗,两组均连续治疗4周。比较两组临床疗效,治疗前后中文版眩晕障碍量表(DHI)评分,并观察两组治疗期间不良反应发生率。结果观察组总有效率高于对照组(P<0.05)。治疗前两组DHI评分比较,差异无统计学意义(P>0.05);治疗后观察组DHI评分低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论清脑醒神汤联合倍他司汀治疗周围性眩晕的临床疗效确切,可降低患者眩晕程度,且安全性较高。Objective To explore the clinical efficacy and safety of Qingnaoxingshen decoction combined with betahistine for peripheral vertigo.Methods A total of 80 cases of patients with peripheral vertigo were selected from 2018 in Maoming Hospital of Traditional Chinese Medicine,which were divided into control group and observation group according to the random number table method,40 cases each of group.The control group was treated with betahistine,the observation group was treated with Qingnaoxingshen decoction based on the control group,both groups were treated for 4 weeks.The clinical effect,DHI score before and after treatment were compared between the two groups,and the incidence rate of adverse reactions during treatment was observed.Results The total effective rate of the observation group was higher than the control group(P<0.05).There was no significant difference in DHI score between the two groups before treatment(P>0.05).After treatment,DHI score of the observation group was lower than the control group(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion The clinical effect of Qingnaoxingshen decoction combined with betahistine for peripheral vertigo is accurate,which can reduce the degree of vertigo,and with high safety.

关 键 词：眩晕 清脑醒神汤 倍他司汀 治疗结果 安全性 

分 类 号：R764.3[医药卫生—耳鼻咽喉科]